VIDEO

Cancer Doesn’t Care About Your Model | DeepGeeks Episode 2

The algorithm is not the bottleneck in cancer research. Infrastructure is. That's the provocative claim at the heart of this episode — and Jessica Audette has built the proof. At Memorial Sloan Kettering Cancer Center, she led the deployment of IRIS, a supercomputer ranked #2 in the U.S. and #4 globally on the IO500 production list. The result: what once took years now takes months. What took months now takes weeks.

Transcript

00:00

How Real-World Constraints Shape Medical AI

Jess: Most folks — myself included, at times — are mystified by technology and the capabilities it can offer. We often have this Veruca Salt mentality: if you’ve seen Willy Wonka, “don’t care how, I want it now.” The researchers don’t want to — and shouldn’t need to — figure out how to get from point A to point B. We want them to focus their efforts on ending cancer for life.

Serena: Welcome to DeepGeeks. I’m Dr. Serena Huang. We spend a lot of time in this industry talking about speed — faster inference, faster training, faster iteration — but there’s a place where speed isn’t just about competitive advantage. It’s about whether a patient gets a diagnosis in time.

My grandma survived cancer twice. She is 94. I just got back from visiting her last week, and I’ve been thinking a lot about her in preparing for today’s conversation, because what my guest is building is for people exactly like her.

Our guest today leads one of the most ambitious research infrastructure teams in the country at Memorial Sloan Kettering Cancer Center. She is here to talk about what it actually takes to build at that scale, what’s still in the way, and what AI looks like when the stakes are as high as they get.

Jessica Audette, Head of Enterprise Infrastructure Strategy and Transformation at Memorial Sloan Kettering.

Now, as I look at your background — infrastructure and cancer research — that’s not a typical combination. I’m curious if you can share with us how you got here, and perhaps more importantly, what kept you here.

01:55

Jess's Origin Story: From Brooklyn to MSKCC

Jess: Well, thank you for having me, Dr. Huang. I am really thrilled to be able to share the work we’re doing, and I certainly did not have a linear career path. Like many millennials, I graduated at the height of the recession. I remember my first job — I was making $10 an hour in Brooklyn. Back then I used to know all the places to get free food.

Technology has really always been a passion of mine. Being a millennial, we were on the cusp — from zero tech to the days where your mom would tell you to be home when the street lights come on, to the tech boom with PCs and the worldwide web. That’s kind of where my love started.

Largely my career has been in the financial industry, but a colleague reached out to me about an opportunity at MSKCC. That was a thrill for my parents, who have been in the medical field as physician assistants since 1985 — at least one of their three children would be in the medical field. I had a degree of separation, but they were just tickled by that.

As you said, there aren’t many of us who haven’t experienced cancer, been directly affected by cancer, or know someone who has. The mission of ending cancer for life — MSKCC’s mission — is a noble mission to stand behind, and that’s what ultimately keeps everyone coming back.

03:31

The Algorithm Isn't the Bottleneck — Infrastructure Is

Serena: I love it. I think we need that mission everywhere. I can certainly relate to it, and I know our audience can as well.

Let’s nerd out a little bit. In our preparation for this podcast, you said something very provocative — at least for me, as a recovering data scientist. You said the algorithm is not the real bottleneck in cancer research. How can the algorithm not be the bottleneck? Can you tell us more? What is more important than that?

Jess: It is true — the algorithm is not the bottleneck. Infrastructure is. Research has really been going on for centuries, but the differentiating factor between the researchers of today and yesteryear is that today they have cutting-edge, high-performant infrastructure platforms to help them advance their science and their research. To really aid them in solving complex problems around image analysis, signal processing, complex modeling, and data analysis. When we say the algorithm is not the real bottleneck, it’s because we can work with the algorithm — we can enhance the code, optimize the workflows. But without the platforms, there’s not really a place to put those things.

Serena: Absolutely. A lot of us forget that in cancer research there is a massive amount of data. Think about medical imaging — this is not a small dataset with a few lines of data, not a small spreadsheet. The scale is enormous.

Now that we know infrastructure is the real bottleneck, let’s get specific. IRIS, the supercomputer, is ranked #2 in the U.S. and #4 globally. Congratulations, by the way. You’ve told us it’s able to reduce wall clock time by 30 times — so what would’ve taken years now takes only months in discovery.

We have some audience members who may have never thought about supercomputing before today. What does that actually mean for a researcher sitting in their office on a regular Monday? And did anyone underestimate the power of IRIS?

06:24

Inside IRIS: Building the Autobahn for Ferraris

Jess: Absolutely. Let’s start at the beginning. When we were designing IRIS, we decided to overhaul our entire technology ecosystem — moving away from legacy platforms and tools, consolidating what made sense, and implementing best-in-class solutions for life sciences and AI/ML workloads. Ultimately, we wanted to maximize performance and the amount of research IRIS could support.

So what does that mean for the researchers in the labs? Most folks — myself included, at times — are mystified by technology and the capabilities it can offer. We often have this Veruca Salt mentality: if you’ve seen Willy Wonka, “don’t care how, I want it now.” The researchers don’t want to — and shouldn’t need to — figure out how to get from point A to point B.

So we’ll put it this way: if everyone wants to own a Ferrari, but there’s no road to drive it on, you’re never going to get very far. We don’t want the researchers wasting their time thinking about infrastructure. They want that road there. We want them to focus their efforts on ending cancer for life.

So ultimately, we deployed a cutting-edge network featuring high speed and low latency, as well as several different generations of high-performance computing nodes. But the major change we implemented was our primary file system. We deployed WEKA, a modern enterprise-class file system that runs on NVMe-based flash storage. It has cloud-bursting capabilities for users who want it, and ultimately, the architectural choices have enhanced our data processing capabilities, streamlined our research methodologies, and provided a world-class platform for groundbreaking discoveries.

So essentially — we built the Autobahn for the Ferraris to drive on.

Serena: I love it. That’s a perfect analogy. If there’s no highway, there’s no place for your Ferrari to go.

Jess: You’d just park it in the garage.

Serena: Exactly. Beautiful, but not helpful.

09:45

AI-Powered Scheduling: Getting the Right Patient to the Right Place

Serena: Let’s go to some use cases, because most importantly — what matters is how does this make a difference in the patient’s life and the clinician’s life?

I can’t tell you how many times I’ve had to reschedule and call different offices for something simple. And I can imagine, especially for patients who are wondering if they have cancer — or who now know they do — that’s enormous news. How do I get more scans, get treatment, schedule everything? The last thing you want to figure out is: can I make it to the right doctor’s office on time?

Can you walk us through what scheduling looks like powered by AI?

Jess: Sure, happy to. In any medical organization, scheduling is kind of the entry point for most patients. When undergoing cancer care, you often have a team of clinicians working cohesively on your case — requiring imaging, testing, diagnostics, things of that nature. We have several locations in and around New York City.

We’ve implemented predictive analytic AI for scheduling. This really optimizes both the patient’s and the clinician’s time. Our main campus is located at 1275 York Avenue. We also have a building on 55th, and several others within the area. If you’re doing imaging at the main campus and then need to meet with a physician at 55th, it’s not going to take 10 minutes to get downtown — we know it takes longer than that by cab or train with traffic. Those predictive analytics give schedulers the opportunity to really optimize the timing so that we don’t have missed appointments, we aren’t overlapping, and we’re not making unrealistic expectations of the patient — like being in two places at once.

It really allows clinicians to spend their time where it’s needed most: at the bedside of the patient.

Serena: I love that. I used to have to use Google Maps on top of my calendar just to figure out if I could get through traffic in time. And I hadn’t thought about the clinician’s time either — if they’re waiting because a patient didn’t show up, or someone is late, then everyone after that patient is late and has to wait.

Jess: It’s a domino effect for sure.

12:18

Voice Dictation & Cutting Clinician Paperwork

Jess: And there are other things we’re doing to alleviate administrative burdens on our clinicians, like dictation. We’ve implemented AI voice recognition and dictation to aid them in creating really well-rounded documentation. When a patient departs from a visit, the clinician dictates all of the meeting notes and case notes, and then that goes to a portal that the patient is able to review later.

Serena: That’s amazing. Is that something where patients would need to consent to being recorded, or is it just on the clinician side?

Jess: The patients don’t have any touchpoint with the dictation — that’s an internal process. Think back to what my parents used to do: huge filing cabinets with your last name somehow pinned to them, and they would physically write out their charts. I remember them being home at dinner, writing out charts from their day, and that would get filed away.

This really optimizes the clinician’s time. As soon as they walk out of the room, they can sit down, dictate their notes, and move on to their next case — as opposed to waiting until the end of the day to do all their case notes. They all have their own routines, but this platform gives them the opportunity to say what they need to and move on.

Serena: Love that.

13:46

What Better Scheduling Actually Feels Like — A Personal Story

Serena: So between AI-powered scheduling and voice notes after a visit — have you noticed any changes in the patient experience? Are there any metrics you can share?

Jess: What I will say is that we’ve gotten resounding feedback from patients about the scheduling options available to them.

I’ll share that my mom was a patient of MSKCC. She had a fleet of clinicians working on her case, and she often received treatment in Monmouth County, New Jersey — but would also be in New York City for other appointments. As a patient caregiver at that time, having the scheduling handled meant I wasn’t needing to call and say, “Hey, we can’t make it to Monmouth by 1:30 — we’re still in Manhattan and she’s still getting her radiation, and we’re going to miss this appointment.” That was all taken care of.

In that use case, with my mom and my dad and I being patient caregivers — that was a relief. It allowed me to focus on keeping my mom’s spirits up and spending time with her, just enjoying those moments, as opposed to dealing with all the scheduling madness.

Serena: That is so relatable. Thank you for sharing.

15:36

Wearables & Care at Home: Real-Time Recovery Data

Serena: All right. We talked a little about personalized medicine — wearables are all the rage, and many of us have AI that tells us how we’re doing and how to optimize our health. But you’re doing something different. Can you talk about wearables and personalized medicine from where you sit, and how it’s making a difference for your patients?

Jess: Wearables have been on the scene for a little while now, but they’ve really ramped up in adoption. We’ve implemented wearables at MSKCC — I believe it was 2022 or 2023 — and this really changed the patient experience.

Our wearables aren’t like a general-purpose smartwatch that does all sorts of things. This is purely for the clinical needs of MSKCC. We’ve implemented these wearables and they’ve changed the experience for patients because they provide the clinical team with real-time data while patients are recovering from the comfort of their home. We call it “Care at Home.”

Cancer treatment inevitably causes patients to become immunocompromised, and in certain cases it may be best for them to recover outside of the hospital. This program allows them to do that — be with their family, be in the comfort of their homes — while still transmitting data back to their clinicians and care team. That live data ensures they’re recovering in the best possible manner.

And it also keeps immunocompromised patients out of the hospital, where they face additional health risks.

Serena: That is so important. Sometimes we think the hospital is the best place for care, but for certain patients, that simply is not the case.

18:03

Meet Amelia: MSKCC's Agentic AI on the Help Desk

Serena: Shifting to another super hot topic — agentic AI. It is everywhere now. It seems like everyone has agentic AI in their company, in their home. At MSKCC, you’ve deployed an agent called Amelia. Can you share what she does and how she’s making an impact?

Jess: In the digitized world, we’re all expecting really fast responses — and that’s no different in our organization, where physicians and other technologists want fast resolutions to tech-related issues. So much so that it’s faster than humans can deliver when dealing with thousands of tickets across an organization as large as ours.

So we deployed agentic AI named Amelia. This is our internal agent that works on our help desk. We wanted to reduce call wait times and redundant work. Our human resources were spending a lot of time on what we call Level 1 issues: “I got locked out of my computer,” “I need my password reset,” “Can I get an account for this?”

By implementing Amelia for our help desk, we reduced our call wait time from 42 minutes down to a minute, with about a 35% cost savings for the organization.

What does that mean? Because a lot of people say, “Oh my gosh, AI is going to take my job” — but this opportunity allowed us to elevate our human resources to focus on high-level solutioning. Amelia handles the redundant requests: “I got locked out of my computer,” “This printer isn’t working,” “My tap-to-go isn’t working.” She’ll either open a ticket for a higher-level agent to come out and service, or she’ll handle it herself.

Now, the fear-mongering that comes in is: where are the graduates going to go? Level 1 used to be the entry point for graduate students. I don’t think those concerns are entirely wrong. I think there’s going to need to be a fundamental shift on the education side of things. But I also think this is going to be a transformation in the way we work. What would’ve been Level 1 and entry-level previously will now maybe be Level 2 — and that becomes the entry point for our graduate students.

Serena: Wait — did you say 42 minutes to one minute?

Jess: 42 minutes down to about a minute. Yes. With 35% cost savings.

Serena: That’s incredible. I can imagine people are much happier — we need tech to work yesterday.

Jess: Yes, exactly.

21:33

Deploying AI Safely in Regulated Environments

Serena: Agentic AI in a regulated industry like yours can cause a lot of concern. When AI is making decisions without human input, what happens? Beyond job loss fears, there’s also concern about agentic AI making the wrong call. What made Amelia safe enough to deploy in a regulated environment like MSKCC?

Jess: I think this is where I recommend you bring a sweet treat to your CISO and work collaboratively with that team. But for us, the question was: what are we trying to solve for? We have brilliant technologists at this organization who were being burdened by redundant work — work that could be automated to free them up to focus on higher-level solutioning and become more innovative instead of reactive to thousands of incoming tickets every month.

We’re a highly regulated industry dealing with patient health information. We worked collaboratively with our security and InfoSec departments to ensure whatever we were planning to stand up would satisfy security and compliance requirements. That would be my first recommendation to anyone looking at this.

Serena: I love that. For anyone working in AI — those are your friends. And a little cupcake won’t hurt.

Jess: It goes a long way.

23:04

How to Start with Agentic AI: Strategy Before Deployment

Serena: If someone is looking to start with agentic AI — regulated industry or not — how do you help them think about where to begin?

Jess: A lot of times people jump on the train without knowing what direction they want to take it. As much as we want to get ahead of the curve in technology, when deploying AI it’s important to have a strategy surrounding your plan. What are you trying to solve for? What roadblocks are you looking to alleviate? What will AI make better? Those are the questions I recommend people take a minute and think about, because just deploying AI to deploy AI — it’s like having the cool Ferrari on the block. It’s not going anywhere if you don’t have the road to drive it on and the destination in mind.

Serena: So true. Years ago it was “data is the new oil” — now AI has become the shiny object, and we forget the most important questions: What are we trying to do? What KPI will this improve? What outcomes are we looking for? We need alignment on the problem before we pick the solution. And it may not be AI if we don’t even know where we’re going.

Jess: For my fellow geeks who are into Lord of the Rings: do not become a Gollum. “My precious” is not going to solve all your issues and questions. Review the KPIs. What is it going to solve? What is it going to achieve? How is it going to help the organization? What ROI are you looking to see?

25:46

Is There Such a Thing as Too Fast in Cancer Research?

Serena: We started this conversation talking about speed — and speed is critically important in cancer research. But is there such a thing as too fast in discovery? How do you balance acceleration with responsible AI principles? What guardrails exist at MSKCC?

Jess: And this episode is not sponsored by Ferrari — but when you’re saving lives, the answer is no. Speed matters. The performance of the platform matters, because faster turnaround times mean treatment plans, vaccinations, immunotherapies, and clinical trials are getting into the hands of clinicians that much faster, which means they’re reaching the patient bedside that much faster.

Of course, we want to implement platforms that are secure, ethical, and really well thought out. Speed is of the utmost importance in cancer care, but our organization has done a phenomenal job working collaboratively with our network and InfoSec teams to ensure we’ve put the right guardrails around the platforms. Any patient health information being leveraged on those platforms is de-identified, further encrypted, and surrounded by more secure protocols.

And for IRIS specifically — the data is de-identified. So it was an easy MVP on that front.

Serena: That makes it so much easier. For anyone working with patient data or sensitive personal data in general — finding a way to de-identify helps de-risk getting started with AI.

Jess: Indeed.

27:26

Magic Wand: Solving Capacity Planning

Serena: If you could fix one thing in medical AI infrastructure — if I gave you a magic wand today — what would you do with it?

Jess: Capacity planning is the bane of my existence. I like to say we have known knowns and known unknowns.

The known knowns are our researchers, our existing labs, their workloads. We collaborate with them to understand their future needs and plan accordingly.

Then we have our known unknowns. We know we want to hire and retain the best and brightest medical personnel and researchers. We don’t know how many we’re going to hire, or how many people they’ll bring with them — whether it’s a lab of 8 to 10 or a lab of 1. We don’t know what their needs will look like or what medical instrumentation they’ll be using. Just last year, we onboarded 48 new medical instruments in the organization — and that just screams storage needs to me.

So how do we address that and show the business the ROI of continued infrastructure investment? I was able to go back through grants awarded to MSKCC and identify those that were awarded specifically because of the high-performance computing platform available to researchers. I shared that over $184 million in grant funding was brought to the institution because of that platform.

Having those metrics to translate technology needs into business justifications has helped us show the light on why this is an important investment — for our research community, our clinicians, and our patients.

Serena: $184 million. That is not chump change. Congratulations. Wow.

30:29

What the Industry Gets Wrong About Innovation

Serena: One last question. Innovation — the word gets tossed around so much, especially in AI and tech. From your perspective, what does the industry get completely wrong about what innovation actually means?

Jess: This is a great question, and I’m going to get a little philosophical if I may. Innovation to me equates to change and progress. There was a time when we were all fearful of computers, and now they’re just ingrained in everyday life. There’s a lot of fearmongering around AI taking over people’s jobs, but I see it as augmentation to human resources. I don’t think anybody is going to lose their job — AI will enable people to think at a higher level and work at a faster pace.

AI will be transformative in the future of work, and it’ll take a mindset shift for us all to become comfortable with that.

If you’re familiar with the Japanese art known as kintsugi — where broken pottery is repaired with gold — I would say that with technology, we need to get a bigger hammer to create something progressive and life-altering. Then build those pieces back up into something beautiful.

Serena: For those less familiar — you’re describing the broken ceramic bowls pieced back together with beautiful gold. Yes?

Jess: Exactly. They put it back together with beautiful gold. The methodology behind that is: you may have started with something beautiful, but through the process of breaking and rebuilding, you create something even more beautiful. I think we have a foundation for transformative change with AI coming to the forefront. It’s been around for a long time, but now it’s getting its spotlight. It’s going to take a mindset shift for folks to become more comfortable with it — and I think it’s one of those known unknowns that makes people nervous.

Serena: Thank you. That is so insightful. Thank you, Jess, for joining us today. I’ve learned a ton, and I know our audience will appreciate all your insights as well.

Jess: Thank you so much. It was such a pleasure to be here, and I’m grateful for the opportunity to discuss AI and hopefully allay some fears.

Serena: Absolutely. I feel inspired — and I know our audience will be too. Thank you.

Serena: Thanks for listening to DeepGeeks. A huge thank you to our guest today, Jessica Audette. If today’s episode makes you think differently about how AI gets built or powered, share it with someone who needs to hear it. Find DeepGeeks on Spotify, YouTube, or wherever you get your podcasts. Until next time.